EAM
SWTX

Eagle Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Eagle Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$9.3M Sell
273,479
-54,366
-17% -$2.03M 0.05% 309
2024
Q2 		$12.6M Buy
+327,845
New +$13.8M 0.07% 247

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Eagle Asset Management's SWTX Position: Q3 2024 in Review

Eagle Asset Management reduced its SpringWorks Therapeutics (SWTX) stake by 17% in Q3 2024, selling an estimated $2.03M and leaving 273,479 shares worth $9.3M. The position accounts for 0.05% of the portfolio, ranked #309.

Eagle Asset Management first reported a position in SWTX in Q2 2024 and has held it in 2 quarters since. The position peaked at $12.6M in Q2 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Eagle Asset Management held 273,479 shares of SpringWorks Therapeutics worth $9.3M as of Q3 2024.
  • Eagle Asset Management sold 54,366 SpringWorks Therapeutics shares in Q3 2024, an estimated $2.03M.
  • SpringWorks Therapeutics made up 0.05% of Eagle Asset Management's portfolio in Q3 2024, its #309 holding.
  • Eagle Asset Management first reported a position in SpringWorks Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Eagle Asset Management's SpringWorks Therapeutics position peaked at $12.6M in Q2 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.